Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15820941rdf:typepubmed:Citationlld:pubmed
pubmed-article:15820941lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:15820941lifeskim:mentionsumls-concept:C0032854lld:lifeskim
pubmed-article:15820941lifeskim:mentionsumls-concept:C0023434lld:lifeskim
pubmed-article:15820941lifeskim:mentionsumls-concept:C0017337lld:lifeskim
pubmed-article:15820941lifeskim:mentionsumls-concept:C0026882lld:lifeskim
pubmed-article:15820941lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:15820941lifeskim:mentionsumls-concept:C0376315lld:lifeskim
pubmed-article:15820941lifeskim:mentionsumls-concept:C1561558lld:lifeskim
pubmed-article:15820941lifeskim:mentionsumls-concept:C0449450lld:lifeskim
pubmed-article:15820941lifeskim:mentionsumls-concept:C1515021lld:lifeskim
pubmed-article:15820941lifeskim:mentionsumls-concept:C2698393lld:lifeskim
pubmed-article:15820941pubmed:issue4lld:pubmed
pubmed-article:15820941pubmed:dateCreated2005-4-11lld:pubmed
pubmed-article:15820941pubmed:abstractTextThe immunoglobulin VH gene mutation status is a strong prognostic indicator in B-cell chronic lymphocytic leukemia (CLL), since unmutated VH genes are correlated with short survival. However, the traditional cut-off level dividing mutated and unmutated cases, i.e. more or less than 2% mutations, has been questioned and other cut-offs have been suggested. We investigated whether an alternative cut-off should be applied and the relation of mutational status to another prognostic marker, Binet staging.lld:pubmed
pubmed-article:15820941pubmed:languageenglld:pubmed
pubmed-article:15820941pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15820941pubmed:citationSubsetIMlld:pubmed
pubmed-article:15820941pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15820941pubmed:statusMEDLINElld:pubmed
pubmed-article:15820941pubmed:monthAprlld:pubmed
pubmed-article:15820941pubmed:issn1592-8721lld:pubmed
pubmed-article:15820941pubmed:authorpubmed-author:KarlssonKarin...lld:pubmed
pubmed-article:15820941pubmed:authorpubmed-author:TobinGerardGlld:pubmed
pubmed-article:15820941pubmed:authorpubmed-author:ThunbergUlfUlld:pubmed
pubmed-article:15820941pubmed:authorpubmed-author:SöderbergOlaOlld:pubmed
pubmed-article:15820941pubmed:authorpubmed-author:HultdinMagnus...lld:pubmed
pubmed-article:15820941pubmed:authorpubmed-author:SundströmChri...lld:pubmed
pubmed-article:15820941pubmed:authorpubmed-author:RoosGöranGlld:pubmed
pubmed-article:15820941pubmed:authorpubmed-author:RosenquistRic...lld:pubmed
pubmed-article:15820941pubmed:authorpubmed-author:VilpoJuhaniJlld:pubmed
pubmed-article:15820941pubmed:authorpubmed-author:MerupMatsMlld:pubmed
pubmed-article:15820941pubmed:authorpubmed-author:AleskogAnnaAlld:pubmed
pubmed-article:15820941pubmed:authorpubmed-author:LaurellAnnaAlld:pubmed
pubmed-article:15820941pubmed:authorpubmed-author:WillanderKers...lld:pubmed
pubmed-article:15820941pubmed:issnTypeElectroniclld:pubmed
pubmed-article:15820941pubmed:volume90lld:pubmed
pubmed-article:15820941pubmed:ownerNLMlld:pubmed
pubmed-article:15820941pubmed:authorsCompleteYlld:pubmed
pubmed-article:15820941pubmed:pagination465-9lld:pubmed
pubmed-article:15820941pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:15820941pubmed:meshHeadingpubmed-meshheading:15820941...lld:pubmed
pubmed-article:15820941pubmed:meshHeadingpubmed-meshheading:15820941...lld:pubmed
pubmed-article:15820941pubmed:meshHeadingpubmed-meshheading:15820941...lld:pubmed
pubmed-article:15820941pubmed:meshHeadingpubmed-meshheading:15820941...lld:pubmed
pubmed-article:15820941pubmed:meshHeadingpubmed-meshheading:15820941...lld:pubmed
pubmed-article:15820941pubmed:meshHeadingpubmed-meshheading:15820941...lld:pubmed
pubmed-article:15820941pubmed:meshHeadingpubmed-meshheading:15820941...lld:pubmed
pubmed-article:15820941pubmed:meshHeadingpubmed-meshheading:15820941...lld:pubmed
pubmed-article:15820941pubmed:meshHeadingpubmed-meshheading:15820941...lld:pubmed
pubmed-article:15820941pubmed:meshHeadingpubmed-meshheading:15820941...lld:pubmed
pubmed-article:15820941pubmed:meshHeadingpubmed-meshheading:15820941...lld:pubmed
pubmed-article:15820941pubmed:year2005lld:pubmed
pubmed-article:15820941pubmed:articleTitlePatients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome.lld:pubmed
pubmed-article:15820941pubmed:affiliationDept. of Genetics and Pathology, Uppsala University, Uppsala, Sweden.lld:pubmed
pubmed-article:15820941pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15820941pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed